Personalis, Inc.
PSNL · Healthcare
$17.06
Caricamento grafico…
Notizie
Ultime notizie su questo titolo
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).
Why Tempus AI Skyrocketed This Week
Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.